TTOO

T2 Biosystems, Inc.
CAPPED RATING

T2 Biosystems Inc is an in vitro diagnostic company. It has developed the proprietary platform that enables direct detection of pathogens, biomarkers and other abnormalities across various unpurified patient sample types.

T2 Biosystems, Inc. (TTOO) is rated C (2.2/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (C+); its weakest is Revisions (D). The rating has held at C for 25 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
D
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY 27.6%
Gross Margin 27.8%
Price Return 3M 25.0%
Price Return 12M -98.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE -138.5%

Historical Factor Score Progression

Held C for 25 weeks
Date Value Growth Profitability Momentum Revisions Overall
2021-06-30 C+ (2.5) C+ (2.6) C- (2.1) C- (2.1) D (1.5) C (2.2)
2020-12-31 C+ (2.5) A- (4.1) D- (1.1) C- (2.1) D (1.5) C (2.3)
2020-09-30 C+ (2.5) C+ (2.5) D+ (1.7) C- (2.1) D (1.4) C- (2.1)